Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 11, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital transactions.
- Shares Repurchased: 3,700,000 ordinary shares.
- Repurchase Price: 1,091.57 pence per share.
- Treasury Shares Held: 484,194,158 shares (representing 8.97% of total voting rights).
- Shares in Issue: 5,399,834,764 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 3,700,000 shares on April 11, 2008. Consequently, the number of shares held in Treasury increased to 484,194,158, while the number of shares in issue remains 5,399,834,764. The filing does not provide comparative data for prior periods regarding these specific capital metrics.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities. No specific risks or contingencies are detailed beyond the standard regulatory compliance with the Financial Services Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total cost of the share repurchase (3,700,000 shares at 1,091.57 pence each) against the company's cash position in other financial reports.
- Confirm the updated share count of 5,399,834,764 in issue for calculating earnings per share (EPS) and voting rights.
- Note that Treasury shares now represent 8.97% of total voting rights, which may impact dilution calculations.
- Ensure the repurchase aligns with the authorization limits set by shareholders at the May 23, 2007 Annual General Meeting.